Many of these patients are naturally curious
about flibanserin, or Addyi — the little pink pill that received FDA approval last year.
Not exact matches
Boehringer Ingelheim stepped away from
flibanserin after the FDA rejected the drug due to concerns
about its efficacy and safety; Goldstein persuaded the Whiteheads to step in.
Valeant Pharmaceuticals International Inc. said on Thursday it would buy Sprout Pharmaceuticals, whose drug
flibanserin (Addyi) became the first approved treatment for low sexual desire in women, for
about $ 1 billion with milestone payments.
As the three clinical trials progressed over the course of
about 8 years, so did techniques in determining desire, says Kingsberg, a reproductive biology and psychology researcher at University Hospitals Case Medical Center in Cleveland, Ohio, and consultant to Sprout Pharmaceuticals, which bought
flibanserin from Boehringer Ingelheim in 2011, and was in turn purchased last week by Valeant Pharmaceuticals.
Debates
about the condition aside, Boehringer Ingelheim, the company that originally developed
flibanserin, and Sprout, which acquired the drug in 2012, tested the drug in clinical trials in which 1,227 women diagnosed with HSDD received the now - approved 100 - milligram dose at bedtime.